Alector, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $214.4M
- Price
- $1.92
- % Change (Daily % change from the live per-ticker quote feed.)
- +6.08%
- Volume
- 4.0M
About
Alector, Inc. operates as a clinical-stage biopharmaceutical company, which engages in pioneering of immuno-neurology. It develops portfolio of innate immune system programs, designed to functionally repair genetic mutations and enable the rejuvenated immune cells to counteract emerging brain pathologies. Its treatment targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. The company was founded by Asa Abeliovich, Errik B. Anderson, Tillman U. Gerngross, and Arnon Rosenthal in May 2013 and is headquartered in South San Francisco, CA.
Quick stats
Shares outstanding111.7M
Computed float92.3M
Float / shares82.6%
Cash runway (months)9.1
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001653087
Websitehttps://www.alector.com
AI Summary
AI-generated1/13
minorneutralother
Alector to Host Virtual Research and Development Event Highlighting Wholly Owned Alector Brain Carrier (ABC)- Enabled Pipeline
Alector announced a virtual R&D event on October 13, 2026 at 8:00 a.m. PT to highlight its wholly owned ABC blood-brain barrier platform and ABC-enabled pipeline.
The agenda features AL137, the lead anti-amyloid beta antibody designed for monthly subcutaneous dosing, plus ABC-enabled siRNA programs AL164 (tau), AL062 (alpha-synuclein) and ADP065 (NLRP3).
The company plans to present preclinical data showing potent target reduction across multiple brain regions; this is an event notice, not a data disclosure.